Attempting to Avoid Chemotherapy in CLL with Lenalidomide and Rituximab
The current study, reporting on the upfront use of lenalidomide and rituximab in CLL, suggests high response rates and excellent tolerability in younger as well as older patients, albeit with a modest median progression-free survival.